Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prime Medicine (PRME) Income towards Parent Company (2021 - 2025)

Prime Medicine filings provide 5 years of Income towards Parent Company readings, the most recent being -$47.5 million for Q4 2025.

  • On a quarterly basis, Income towards Parent Company fell 12.42% to -$47.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$204.8 million, a 4.57% decrease, with the full-year FY2025 number at -$204.2 million, down 4.25% from a year prior.
  • Income towards Parent Company hit -$47.5 million in Q4 2025 for Prime Medicine, up from -$52.8 million in the prior quarter.
  • In the past five years, Income towards Parent Company ranged from a high of -$16.4 million in Q3 2021 to a low of -$65.6 million in Q4 2023.
  • Median Income towards Parent Company over the past 5 years was -$46.6 million (2024), compared with a mean of -$44.4 million.
  • The widest YoY moves for Income towards Parent Company: up 37.56% in 2022, down 78.83% in 2022.
  • Prime Medicine's Income towards Parent Company stood at -$62.9 million in 2021, then surged by 37.56% to -$39.3 million in 2022, then tumbled by 67.1% to -$65.6 million in 2023, then surged by 35.6% to -$42.3 million in 2024, then decreased by 12.42% to -$47.5 million in 2025.
  • The last three reported values for Income towards Parent Company were -$47.5 million (Q4 2025), -$52.8 million (Q3 2025), and -$52.6 million (Q2 2025) per Business Quant data.